Patents by Inventor Maximiliano Vasquez

Maximiliano Vasquez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES TO BASIC FIBROBLAST GROWTH FACTOR
    Publication number: 20130209482
    Abstract: The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: December 15, 2011
    Publication date: August 15, 2013
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Lihong Wang, Hangil Park, Maximiliano Vasquez
  • ANTIBODY LIBRARIES
    Publication number: 20130197201
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
    Type: Application
    Filed: July 14, 2011
    Publication date: August 1, 2013
    Applicant: ADIMAB, LLC
    Inventors: Maximiliano Vasquez, Arvind Sivasubramanian, Michael Feldhaus
  • Endoglin Antibodies
    Publication number: 20120294864
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Application
    Filed: May 31, 2012
    Publication date: November 22, 2012
    Applicant: TRACON PHARMACEUTICALS, INC.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R)
    Publication number: 20120219524
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Application
    Filed: May 4, 2012
    Publication date: August 30, 2012
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Justin Wong, Maximiliano Vasquez
  • Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44
    Publication number: 20120201751
    Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
    Type: Application
    Filed: December 5, 2011
    Publication date: August 9, 2012
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Maximiliano Vasquez
  • Endoglin antibodies
    Patent number: 8221753
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: July 17, 2012
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 8206715
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: June 26, 2012
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Justin Wong, Maximiliano Vasquez
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20120134994
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 31, 2012
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Monoclonal antibodies to fibroblast growth factor receptor 2
    Patent number: 8101723
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: January 24, 2012
    Assignee: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Monoclonal antibodies to basic fibroblast growth factor
    Patent number: 8101725
    Abstract: The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: January 24, 2012
    Assignee: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Lihong Wang, Hangil Park, Maximiliano Vasquez
  • Cytotoxicity mediation of cells evidencing surface expression of CD44
    Patent number: 8071072
    Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: December 6, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Maximiliano Vasquez
  • Antibodies That Bind CSF1R
    Publication number: 20110274683
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Application
    Filed: May 4, 2011
    Publication date: November 10, 2011
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Justin Wong, Maximiliano Vasquez
  • Humanized PAI-1 antibodies
    Patent number: 7981415
    Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: July 19, 2011
    Assignee: Cisthera, Inc.
    Inventors: Donald E. Staunton, Maximiliano Vasquez
  • HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE
    Publication number: 20110158986
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: December 22, 2010
    Publication date: June 30, 2011
    Applicants: ELI LILLY CORPORATION, WASHINGTON UNIVERSITY
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Endoglin Antibodies
    Publication number: 20110076263
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Application
    Filed: March 31, 2010
    Publication date: March 31, 2011
    Applicant: TRACON PHARMACEUTICALS, INC.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • Humanized antibodies that sequester amyloid beta peptide
    Patent number: 7892545
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: February 22, 2011
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Anti-CCR5 antibody
    Patent number: 7851600
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: December 14, 2010
    Assignees: Progenics Pharmaceuticals Inc., Facet Biotech Corporation
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
  • Humanized antibodies that recognize Verotoxin II and cell line producing same
    Patent number: 7846435
    Abstract: The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: December 7, 2010
    Assignees: Teijin Limited, PDL Biopharma, Inc.
    Inventors: Yoh-Ichi Matsumoto, Atsuchi Imaizumi, Tsuyoshi Kimura, Tae Takeda, Yoshifumi Takeda, legal representative, Man Sung Co, Maximiliano Vasquez
  • Humanized Monoclonal Antibodies to Hepatocyte Growth Factor
    Publication number: 20100278815
    Abstract: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: September 29, 2009
    Publication date: November 4, 2010
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Maximiliano Vasquez
  • Humanized PAI-1 Antibodies and Uses Thereof
    Publication number: 20100254979
    Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.
    Type: Application
    Filed: March 8, 2010
    Publication date: October 7, 2010
    Applicant: CISTHERA, INCORPORATED
    Inventors: Donald E. Staunton, Maximiliano Vasquez